Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05747053 · ClinicalTrials.gov registry record
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
A clinical trial, sponsored by George Washington University.
- Terminated
- Registry status
- 105
- Enrollment target
NCT05747053: Clinical Trial study, sponsored by George Washington University.
NCT05747053 is a clinical trial that was terminated before completion, run by George Washington University. The registered enrollment target is 105 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05747053 was terminated before completion, sponsored by George Washington University.
- TERMINATED
- Registry status
- 105 participants
- Enrollment target
Study Summary
Long-term graft failure rates continue to be unacceptably high despite the development of immunosuppressive drugs, underscoring the unmet need for robust prognostic biomarkers of allograft injury and failure. While rates of acute rejection (AR) continue to decrease, it remains the strongest predictor of long-term allograft survival, and so having a better understanding of factors predicting AR may contribute to more individualized patient care. Selecting optimum immunosuppressive dosage is another factor in personalizing kidney care. This project will study two areas of individualized kidney care: 1) assessing rejection by surveillance testing utilizing AlloSure, 2) developing an algorithm to select optimum immunosuppressive medication dosage.
Primary Outcome
Examine if AlloSure predicts the incidence of active, chronic Active antibody mediated rejection (cAMR) and cellular rejection in high risk patients. This will be assessed through observing the changes in AlloSure values one draw after another.
Interventions
- DIAGNOSTIC_TEST AlloSure
- DIAGNOSTIC_TEST PAXGene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2022-12-08 |
Why NCT05747053 stopped before completion
NCT05747053 is an observational study that tracks outcomes without assigning an intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which AlloSure is the first listed.
NCT05747053 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05747053 about?
NCT05747053 is a clinical study titled "Personalization of Immunosuppressive Treatment for Organ Transplant Recipients". Long-term graft failure rates continue to be unacceptably high despite the development of immunosuppressive drugs, underscoring the unmet need for robust prognostic biomarkers of allograft injury and failure. While rates of acute rejection (AR) continue to decrease, it remains the strongest predicto...
What is the current status of trial NCT05747053?
This trial is currently terminated. The enrollment target is 105 participants. The study started on 2020-10-01. Estimated completion is 2022-12-08.
What interventions are being tested in trial NCT05747053?
The interventions under investigation include: AlloSure (DIAGNOSTIC_TEST), PAXGene (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05747053?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI